Leptomeningeal metastases from genitourinary cancer

The University of Texas MD Anderson Cancer Center experience

Shlomit Yust-Katz, Samuel Mathis, Morris D. Groves

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Leptomeningeal metastasis (LM) most commonly arise from breast and lung cancers, and melanoma. Genitourinary cancer (including ovarian, prostate, uterine kidney and bladder) rarely cause LM, with only case reports published. The aims of the study were to describe cases of patients with Genitourinary cancer and Leptomeningeal metastasis, to estimate its prevalence and describe its behavior and outcome. We queried the MD Anderson database for patients with LM and genitourinary cancer between 1978 and 2011. The files of all patients with genitourinary cancer and leptomeningeal disease were retrospectively reviewed. Out of 93960 GU cancer patients treated in MD Anderson (cervix cancer 13,289, ovarian cancer 13,126, bladder cancer 11,834, prostate cancer 41,830, and kidney 13,881), 31 cases (0.03 %) of GU cancer with LM were identified in MD Anderson Cancer Center (MDACC) between 1978 and 2011. Eight patients had bladder cancer, 4 had cervical cancer, 4 had renal cancer, 8 had ovarian cancer and 7 had prostate cancer. Mean age of diagnosis of cancer was 55.9 ± 11.7 (range 20-74). Mean time from primary diagnosis to LM diagnosis was 141.46 ± 244 weeks (range 0.43-409.57). Median survival after LM diagnosis was 15.7 weeks (range 0.85-142.57). The patients presented with multiple signs and symptoms. Although rare - LM should be considered as a complication of GU cancer. Awareness of early neurological signs and symptoms may help the clinician to make an early diagnosis and possibly intervene to prevent neurological deficits.

Original languageEnglish (US)
Article number429
JournalMedical Oncology
Volume30
Issue number1
DOIs
StatePublished - Mar 1 2013

Fingerprint

Urogenital Neoplasms
Neoplasm Metastasis
Neoplasms
Urinary Bladder Neoplasms
Uterine Cervical Neoplasms
Ovarian Neoplasms
Signs and Symptoms
Prostatic Neoplasms
Kidney
Kidney Neoplasms
Prostate
Early Diagnosis
Melanoma
Lung Neoplasms
Urinary Bladder
Databases
Breast Neoplasms

Keywords

  • Genitourinary cancer
  • Leptomeningeal metastases
  • MD Anderson Cancer Center

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Leptomeningeal metastases from genitourinary cancer : The University of Texas MD Anderson Cancer Center experience. / Yust-Katz, Shlomit; Mathis, Samuel; Groves, Morris D.

In: Medical Oncology, Vol. 30, No. 1, 429, 01.03.2013.

Research output: Contribution to journalArticle

@article{ca2bf90b03b043ff87aa4f8005fcc28a,
title = "Leptomeningeal metastases from genitourinary cancer: The University of Texas MD Anderson Cancer Center experience",
abstract = "Leptomeningeal metastasis (LM) most commonly arise from breast and lung cancers, and melanoma. Genitourinary cancer (including ovarian, prostate, uterine kidney and bladder) rarely cause LM, with only case reports published. The aims of the study were to describe cases of patients with Genitourinary cancer and Leptomeningeal metastasis, to estimate its prevalence and describe its behavior and outcome. We queried the MD Anderson database for patients with LM and genitourinary cancer between 1978 and 2011. The files of all patients with genitourinary cancer and leptomeningeal disease were retrospectively reviewed. Out of 93960 GU cancer patients treated in MD Anderson (cervix cancer 13,289, ovarian cancer 13,126, bladder cancer 11,834, prostate cancer 41,830, and kidney 13,881), 31 cases (0.03 {\%}) of GU cancer with LM were identified in MD Anderson Cancer Center (MDACC) between 1978 and 2011. Eight patients had bladder cancer, 4 had cervical cancer, 4 had renal cancer, 8 had ovarian cancer and 7 had prostate cancer. Mean age of diagnosis of cancer was 55.9 ± 11.7 (range 20-74). Mean time from primary diagnosis to LM diagnosis was 141.46 ± 244 weeks (range 0.43-409.57). Median survival after LM diagnosis was 15.7 weeks (range 0.85-142.57). The patients presented with multiple signs and symptoms. Although rare - LM should be considered as a complication of GU cancer. Awareness of early neurological signs and symptoms may help the clinician to make an early diagnosis and possibly intervene to prevent neurological deficits.",
keywords = "Genitourinary cancer, Leptomeningeal metastases, MD Anderson Cancer Center",
author = "Shlomit Yust-Katz and Samuel Mathis and Groves, {Morris D.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1007/s12032-012-0429-z",
language = "English (US)",
volume = "30",
journal = "Medical oncology (Northwood, London, England)",
issn = "1357-0560",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Leptomeningeal metastases from genitourinary cancer

T2 - The University of Texas MD Anderson Cancer Center experience

AU - Yust-Katz, Shlomit

AU - Mathis, Samuel

AU - Groves, Morris D.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Leptomeningeal metastasis (LM) most commonly arise from breast and lung cancers, and melanoma. Genitourinary cancer (including ovarian, prostate, uterine kidney and bladder) rarely cause LM, with only case reports published. The aims of the study were to describe cases of patients with Genitourinary cancer and Leptomeningeal metastasis, to estimate its prevalence and describe its behavior and outcome. We queried the MD Anderson database for patients with LM and genitourinary cancer between 1978 and 2011. The files of all patients with genitourinary cancer and leptomeningeal disease were retrospectively reviewed. Out of 93960 GU cancer patients treated in MD Anderson (cervix cancer 13,289, ovarian cancer 13,126, bladder cancer 11,834, prostate cancer 41,830, and kidney 13,881), 31 cases (0.03 %) of GU cancer with LM were identified in MD Anderson Cancer Center (MDACC) between 1978 and 2011. Eight patients had bladder cancer, 4 had cervical cancer, 4 had renal cancer, 8 had ovarian cancer and 7 had prostate cancer. Mean age of diagnosis of cancer was 55.9 ± 11.7 (range 20-74). Mean time from primary diagnosis to LM diagnosis was 141.46 ± 244 weeks (range 0.43-409.57). Median survival after LM diagnosis was 15.7 weeks (range 0.85-142.57). The patients presented with multiple signs and symptoms. Although rare - LM should be considered as a complication of GU cancer. Awareness of early neurological signs and symptoms may help the clinician to make an early diagnosis and possibly intervene to prevent neurological deficits.

AB - Leptomeningeal metastasis (LM) most commonly arise from breast and lung cancers, and melanoma. Genitourinary cancer (including ovarian, prostate, uterine kidney and bladder) rarely cause LM, with only case reports published. The aims of the study were to describe cases of patients with Genitourinary cancer and Leptomeningeal metastasis, to estimate its prevalence and describe its behavior and outcome. We queried the MD Anderson database for patients with LM and genitourinary cancer between 1978 and 2011. The files of all patients with genitourinary cancer and leptomeningeal disease were retrospectively reviewed. Out of 93960 GU cancer patients treated in MD Anderson (cervix cancer 13,289, ovarian cancer 13,126, bladder cancer 11,834, prostate cancer 41,830, and kidney 13,881), 31 cases (0.03 %) of GU cancer with LM were identified in MD Anderson Cancer Center (MDACC) between 1978 and 2011. Eight patients had bladder cancer, 4 had cervical cancer, 4 had renal cancer, 8 had ovarian cancer and 7 had prostate cancer. Mean age of diagnosis of cancer was 55.9 ± 11.7 (range 20-74). Mean time from primary diagnosis to LM diagnosis was 141.46 ± 244 weeks (range 0.43-409.57). Median survival after LM diagnosis was 15.7 weeks (range 0.85-142.57). The patients presented with multiple signs and symptoms. Although rare - LM should be considered as a complication of GU cancer. Awareness of early neurological signs and symptoms may help the clinician to make an early diagnosis and possibly intervene to prevent neurological deficits.

KW - Genitourinary cancer

KW - Leptomeningeal metastases

KW - MD Anderson Cancer Center

UR - http://www.scopus.com/inward/record.url?scp=84880626862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880626862&partnerID=8YFLogxK

U2 - 10.1007/s12032-012-0429-z

DO - 10.1007/s12032-012-0429-z

M3 - Article

VL - 30

JO - Medical oncology (Northwood, London, England)

JF - Medical oncology (Northwood, London, England)

SN - 1357-0560

IS - 1

M1 - 429

ER -